No validated molecular target

The term "No validated molecular target" is a designation used in pharmacology and drug development to indicate that the specific molecular entity responsible for a drug's therapeutic effect has not been identified. This status is frequently associated with drugs identified via phenotypic screening, where compounds are selected based on their ability to alter a disease-relevant phenotype in cells or animal models without prior knowledge of the target (Source: Nature Reviews Drug Discovery). While these compounds may show significant clinical efficacy, the absence of a defined target poses challenges for rational drug design and the prediction of potential side effects. Historically, many widely used medications, such as certain general anesthetics and lithium, were utilized for years before their molecular targets were eventually elucidated or remain partially understood (Source: StatPearls). In modern drug development, identifying the target of a phenotypic hit is a critical step known as target deconvolution, which utilizes techniques like chemical proteomics and genetic interaction mapping (Source: Nature Chemical Biology). Until a target is confirmed, these agents are categorized as having an unknown or unvalidated mechanism of action in databases such as ChEMBL and DrugBank. This classification serves as a placeholder to ensure that the pharmacological activity is recorded even when the molecular biology is not yet fully mapped. Consequently, "No validated molecular target" does not refer to a biological molecule but rather to a gap in current scientific knowledge regarding a drug's interaction.

Other names

Unknown targetUnidentified molecular targetMechanism of action unknownPhenotypic target

The mechanism of action for compounds associated with this entry is unknown or has not been molecularly defined.